**BACKGROUND** A security alert about the possibility of a potentially fatal interaction in patients, especially neonates, was reported by FDA. Patients treated with ceftriaxone and concomitant total parenteral nutrition (TPN), are potentially at risk of pulmonary or intravascular precipitation due to ceftriaxone-calcium complex.

**METHOD / RESULTS**

**Study period:** 2010 March – 2011 May.

Inpatients that required calcium supplemented TPN and concomitant administration of ceftriaxone were selected from:

- **838 total parenteral nutritions elaborated.**
- **85 patients.**
- **16 patients (18.8%), none of them neonate, were detected with TPN and ceftriaxone at the same episode:**
  - 10 mismatched administrations over time.
  - 6 (7%) concomitantly, susceptible of suffering the described interaction

**CONCLUSIONS**

- Less than a tenth part of TPN patients were susceptible of suffering ceftriaxone-calcium interaction in our hospital.
- No neonates were exposed to risk.
- None of the patients had clinical complications due to this interaction.
- Pharmacist TPN application was updated for real-time detection.